IPA ImmunoPrecise Antibodies

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)--

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company’s investor relations representative.

Conference Call:

Date: September 9, 2021

Time: 4:30 p.m. Eastern time

Toll-free dial-in number: 1-877-407-3982

International dial-in number: 1-201-493-6780

Conference ID: 13722893

Webcast:

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at .

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit .

EN
03/09/2021

Underlying

IPAImmunoPrecise Antibodies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ImmunoPrecise Antibodies

 PRESS RELEASE
Free
IPA ImmunoPrecise A...

La filiale d'IPA, BioStrand, résout le dilemme d’intégration de l’info...

VICTORIA, Colombie-Britannique--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ : IPA) (« ImmunoPrecise » ou « IPA » ou la « Société »), une société de recherche et de technologie biothérapeutique optimisée par l’IA, annonce aujourd’hui que sa filiale, BioStrand®, a résolu avec succès le dilemme d’intégration de l’information (DII) en développant une conception technologique unique qui permet à sa technologie HYFT brevetée d’encapsuler et unifier diverses modalités de données — y compris des données syntaxiques (séquences), des données structurelles 3D, des informations scientifiques n...

May 31, 2023 1 FR
 PRESS RELEASE
Free
IPA ImmunoPrecise A...

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemm...

VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3D structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular...

May 30, 2023 1 EN
 PRESS RELEASE
Free
IPA ImmunoPrecise A...

Présentation de l'IPA à la conférence Jefferies Healthcare 2023

VICTORIA, Colombie-Britannique--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ : IPA) (« ImmunoPrecise » ou « IPA » ou la « Société »), une société de recherche et de technologie biothérapeutique alimentée par l'IA, a annoncé aujourd'hui que la Dre Jennifer Bath, cheffe de la direction et présidente de la société, fera une présentation à la Jefferies Healthcare Conference le vendredi 9 juin 2023, à 11 h 00, heure de l'Est. La diffusion de la présentation, en direct et en différé, sera accessible sur le site Web de l'entreprise à l'adresse suivante . Le reprise vidéo de la webdiffusi...

May 17, 2023 1 FR
 PRESS RELEASE
Free
IPA ImmunoPrecise A...

IPA to Present at Jefferies Healthcare Conference 2023

VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time. The live and archived webcast of the presentation will be accessible from the company’s website at . The replay of the webcast will be available for 90 days. About ImmunoPrecise Antibodies Ltd. ImmunoPre...

May 17, 2023 1 EN
 PRESS RELEASE
Free
IPA ImmunoPrecise A...

L’Office européen des brevets accordera la demande de brevet de BioKey...

VICTORIA, Colombie-Britannique--(BUSINESS WIRE)-- Immunoprecise Antibodies Ltd. (NASDAQ : IPA) (« Immunoprecise » ou « IPA » ou la « Société »), société mère de BioKey et filiale de BioStrand, annonce aujourd’hui que l’OEB a émis une « décision d’octroi » pour la demande de brevet de BioKey portant sur la technologie HYFT® de la société utilisée pour organiser et analyser les informations relatives aux séquences biologiques. La technologie et la méthodologie HYFT offrent une nouvelle façon de puiser efficacement dans les informations de séquence, permettant ainsi d’extraire et d’utiliser des i...

March 27, 2023 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch